KR101660834B1 - Anti-diabetic effects of Gypenoside 75 - Google Patents

Anti-diabetic effects of Gypenoside 75 Download PDF

Info

Publication number
KR101660834B1
KR101660834B1 KR1020150059646A KR20150059646A KR101660834B1 KR 101660834 B1 KR101660834 B1 KR 101660834B1 KR 1020150059646 A KR1020150059646 A KR 1020150059646A KR 20150059646 A KR20150059646 A KR 20150059646A KR 101660834 B1 KR101660834 B1 KR 101660834B1
Authority
KR
South Korea
Prior art keywords
present
pharmaceutical composition
diabetes
composition
insulin
Prior art date
Application number
KR1020150059646A
Other languages
Korean (ko)
Inventor
김선창
박찬배
이순장
Original Assignee
재단법인 지능형 바이오 시스템 설계 및 합성 연구단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 filed Critical 재단법인 지능형 바이오 시스템 설계 및 합성 연구단
Priority to KR1020150059646A priority Critical patent/KR101660834B1/en
Application granted granted Critical
Publication of KR101660834B1 publication Critical patent/KR101660834B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23L1/30

Abstract

The present invention relates to a composition for preventing, alleviating, or treating diabetes and, more specifically, relates to a pharmaceutical composition, a food composition, and a feed composition, which comprises gypenoside 75 or a pharmaceutically acceptable salt thereof. In addition, the present invention relates to a method for preventing or treating diabetes, using the composition.

Description

Anti-diabetic effects of Gypenoside 75 < RTI ID = 0.0 >

The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetes comprising zifenoid 75 or a pharmaceutically acceptable salt thereof, and more particularly to a pharmaceutical composition for preventing or treating diabetes comprising phyphnoside 75 or a pharmacologically acceptable salt thereof, A method for preventing or treating diabetes comprising administering an effective amount of a composition to a subject other than a human, a food composition for preventing or improving diabetes comprising zifenoid 75 or a pharmaceutically acceptable salt thereof, zifenoid 75 or a food thereof The present invention relates to a feed composition for preventing or ameliorating diabetes.

Diabetes mellitus, a chronic metabolic disease, is one of the diseases that threatens the health of human beings. It causes diseases such as vascular disorders, nerves, kidneys, and retinas and causes them to lose their lives. Diabetes mellitus is divided into insulin-dependent diabetes (type 1 diabetes) and non-insulin dependent type 2 diabetes (type 2 diabetes), depending on the mechanism that occurs.

Insulin-dependent diabetes mellitus is known to cause insufficient blood glucose because insulin is not produced in the body by selectively damaging or destroying pancreatic beta cells. It is known that insulin-dependent diabetes mellitus is caused by severe hyperglycemia, ketoacidosis, It shows fatigue. Insulin-dependent diabetes mellitus in children or teenagers is the treatment of insulin.

Non-insulin dependent diabetes mellitus accounts for more than 90% of diabetic patients, mainly in adults. The cause of the disease is unknown, but the insulin secretion of pancreatic beta cells is decreased by environmental factors such as genetic factors, abnormal eating habits, stress, exercise, obesity and aging, or insulin resistance increases in liver, muscle and fat tissue Are involved in a complex process. The non-insulin-dependent diabetes mellitus is generally resistant to insulin, and the hyperglycemic state is usually sustained due to insulin action. Chronic hyperglycemia causes damage to pancreatic beta cells and causes apoptosis. Therefore, effective treatment of type 2 diabetes requires effective control of blood sugar, and the function of normal insulin is very important at the center.

In the meantime, in a clinical trial to determine the cause of insulin resistance in the elderly, a comparison between elderly people and young people with similar physical conditions revealed that glucose metabolism was defective in the elderly muscle. In addition, nuclear magnetic resonance analysis showed that mitochondrial activity decreased in the elderly muscle. This result shows that mitochondrial dysfunction in the muscle cells of the elderly can cause non-insulin dependent diabetes mellitus. In fact, it has been found that the expression of the mitochondrial protein ATP synthase β is decreased in the muscle of patients with non-insulin dependent diabetes mellitus (J Biol Chem, 278: 10436-10442 (2003). Eventually, activation of mitochondria is also known to be involved in the treatment of non-insulin dependent diabetes It can be an approach.

Currently, treatment of non-insulin dependent diabetes mellitus includes diet, exercise, and medication. As the drugs used for the treatment of diabetes, various kinds of excellent hypoglycemic agents such as sulfonylurea type, biguanide type, alpha-glycosidase inhibitor type, thiazolidinedione type, meglitinide type and the like are produced and marketed. However, these medications have been associated with hypoglycemia, hypoglycemia (Diabetes Care 1995: 18 (6): 817-824), and severe symptoms such as vomiting, abdominal pain and abdominal distention (International Hepatology Comminications, 5: 289-296 (International Hepatology Comminications, 5: 289-296 (1996)). Furthermore, people who are in a condition such as liver disease, gastrointestinal tract disorder, kidney disease, pregnancy, etc., are limited in their use.

Metformin-based drugs can also effectively inhibit abnormal biosynthetic activity by potently activating AMPK (AMP activated kinase), which plays an important role in glucose metabolism in the liver of the gluconeogenesis pathway, Many pharmaceutical companies are currently manufacturing and selling. However, studies have shown that the greater the dose and duration of metformin, the greater the risk of vitamin B12 deficiency.

Therefore, a wide range of researches have been conducted to develop natural diabetic drugs and functional foods, which have little toxicity and side effects, and have excellent pharmacological activity, and natural products which have been used for herbal medicine and folk medicine from the past. Patent Application No. 2011-0020469 has been filed for an invention relating to a composition for preventing or treating diabetes, which comprises ginsenoside Rg2 and Rg3. Recently, research on prevention and treatment of diabetes has been conducted.

Meanwhile, ginseng contains various kinds of ginsenosides and gypenosides such as Panaxadiol (PD), Panaxatriol (PT), and Oleanane . It is difficult to predict the same effect even with the same system of ginsenoside since the function varies depending on the type thereof, such as enhancement of immune function, central excitatory action, promotion of adrenocorticotropic hormone secretion, and inhibition of platelet aggregation.

Under these circumstances, the inventors of the present invention have made extensive efforts to prevent or treat diabetes mellitus. As a result, the present inventors have found that zifenoid 75 enhances insulin secretion of insulin secreting cells and activates mitochondrial functions of insulin secreting cells to prevent or treat diabetes mellitus The present invention has been completed.

One object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of diabetes comprising zifenoid 75 or a pharmaceutically acceptable salt thereof.

Another object of the present invention is to provide a method of preventing or treating diabetes comprising administering the pharmaceutical composition to a subject other than a human.

Another object of the present invention is to provide a food composition for preventing or improving diabetes comprising zifenoid 75 or a pharmaceutically acceptable salt thereof.

Another object of the present invention is to provide a feed composition for preventing or improving diabetes comprising zifenoid 75 or a pharmaceutically acceptable salt thereof.

According to one aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating diabetes comprising zifenoid 75 or a pharmaceutically acceptable salt thereof.

The ziphenoxide 75 of the present invention may preferably be a ziphenocide 75 having the structure of the following formula (1).

[Chemical Formula 1]

Figure 112015041364097-pat00001

The ziphenocide 75 may be chemically synthesized or separated from a natural substance. When the ziphenocide 75 of the present invention is separated from a natural substance, an extract of a natural substance or a fraction thereof, It can be a concept that includes everything.

The term "pharmaceutically acceptable salt " as used herein means a formulation that does not impair the biological activity and properties of the administered ziphenocide 75. The pharmaceutically acceptable salts may, unless otherwise indicated, include all salts of acidic or basic groups that may be present in the compound of ziphenocide 75. For example, the pharmaceutically acceptable salts may include sodium, calcium and potassium salts of hydroxy groups, and other pharmaceutically acceptable salts of amino groups include hardro-bromide, sulfate, hydrogen sulfate, phosphate, hydrogen (Salicylate) salt, and the like can be given. Examples of the phosphate salt include, but are not limited to, phosphate, dihydrogenphosphate, acetate, succinate, citrate, tartrate, lactate, mandelate, methanesulfonate (mesylate) and p-toluenesulfonate Can be prepared via known methods for preparing salts.

As used herein, the term "prophylactic " means any act that inhibits or delays diabetes by administering the composition of the present invention to an individual.

The term "treatment ", as used herein, refers to any act that allows the composition of the present invention to be administered to an individual in order to improve or improve diabetes symptoms.

The pharmaceutical composition of the present invention has an excellent effect of preventing or treating diabetes by the action of the above-mentioned active ingredient, zifenoid 75 or a pharmaceutically acceptable salt thereof, and it has no toxicity and causes side effects even when applied to human body It is safe without it.

The pharmaceutical composition of the present invention may be used as a single preparation or may be manufactured as a combined preparation containing a drug known to have an approved diabetic therapeutic effect and may be formulated using a pharmaceutically acceptable carrier or excipient May be prepared in unit dosage form or may be manufactured by intrusion into a multi-dose container.

The pharmaceutical composition of the present invention may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols or the like, oral preparations or sterilized injection solutions according to a conventional method Examples of carriers, excipients and diluents that can be included in the composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, But are not limited to, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil and the like. These may be used alone or in combination of two or more.

When the pharmaceutical composition of the present invention is formulated, it can be prepared using diluents or excipients such as fillers, extenders, binders, humectants, disintegrants, and surfactants that are usually used.

Solid formulations for oral administration may include tablets, pills, powders, granules, capsules and the like, which may contain one or more excipients such as starch, calcium carbonate, sucrose, lactose or gelatin. Can be mixed and prepared. In addition to simple excipients, lubricants such as magnesium stearate, talc, and the like may also be used. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have.

Formulations for parenteral administration may include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, external preparations, and the like. Examples of the non-aqueous solution and suspension include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like.

The pharmaceutically effective dose of the pharmaceutical composition of the present invention may be varied depending on the formulation method, the administration mode, the administration time and / or the administration route of the pharmaceutical composition, and the reaction to be achieved by the administration of the pharmaceutical composition The type and severity of the subject to be treated, the type of subject to be treated, age, weight, general health condition, symptom or degree of disease, sex, diet, excretion, drugs used simultaneously or simultaneously with the subject, And other factors well known in the medical arts, and those skilled in the art will readily determine and prescribe dosages that are effective for the desired treatment.

The pharmaceutical composition of the present invention may comprise a pharmaceutically effective amount of ziphenocide 75.

The term "pharmaceutically effective amount" as used herein means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment and is generally in the range of 0.001 to 1000 mg / kg, preferably 0.05 To 200 mg / kg, more preferably 0.1 to 100 mg / kg, may be administered once a day to several times per day. For purposes of the present invention, however, the specific therapeutically effective amount for a particular patient will depend upon the nature and extent of the reaction to be achieved, the specific composition, including whether or not other agents are used, the age, weight, Sex and diet of the patient, the time of administration, the route of administration and the rate of administration of the composition, the duration of the treatment, the drugs used or concurrently used with the specific composition, and similar factors well known in the medical arts.

The content of the extract contained in the pharmaceutical composition is not particularly limited, but may be 0.01 to 100% by weight, more preferably 1 to 80% by weight based on the total weight of the pharmaceutical composition.

The pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or in combination with another therapeutic agent, and may be administered sequentially or simultaneously with conventional therapeutic agents. And can be administered singly or multiply. It is important to take into account all of the above factors and to administer an amount that can achieve the maximum effect in a minimal amount without causing side effects, and can be readily determined by those skilled in the art.

The route of administration and the mode of administration of the pharmaceutical composition of the present invention may be independent of each other and are not particularly limited in the method and may be arbitrarily administered and administered as long as the pharmaceutical composition can reach the desired site It is possible to follow the method. The pharmaceutical composition may be administered orally or parenterally, and preferably parenterally.

The parenteral administration may be, for example, intravenous administration, intraperitoneal administration, intramuscular administration, transdermal administration or subcutaneous administration.

According to another aspect of the present invention, the pharmaceutical composition provides a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

As used herein, the term "pharmaceutically acceptable carrier" may mean a carrier or diluent that does not disturb the biological activity and properties of the compound being injected, without irritating the organism. The type of the carrier that can be used in the present invention is not particularly limited, and any carrier conventionally used in the art and pharmaceutically acceptable may be used. Non-limiting examples of the carrier include saline, sterilized water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol and the like. These may be used alone or in combination of two or more. The carrier may comprise a non-naturally occuring carrier.

In addition, if necessary, other conventional additives such as an antioxidant, a buffer and / or a bacteriostatic agent can be added and used. A diluent, a dispersant, a surfactant, a binder, a lubricant, Pills, capsules, granules or tablets, and the like.

According to another aspect of the present invention, there is provided a pharmaceutical composition wherein the diabetes for prevention or treatment of the pharmaceutical composition is non-insulin dependent diabetes mellitus.

The term "non-insulin dependent diabetes mellitus " used in the present invention is also referred to as type 2 diabetes mellitus and occurs when insulin is secreted, but its amount is insufficient, or insulin that is secreted by the body is not effectively used. Non-insulin-dependent diabetes mellitus accounts for 90% to 95% of all diabetes mellitus. It occurs mainly in the forties, but the age at onset is decreasing and it is also found in children. Symptoms of non-insulin dependent diabetes mellitus include severe thirst, frequent urination, fatigue, and increased hunger.

According to another aspect of the present invention, there is provided a method for preventing or treating diabetes comprising administering to a subject other than a human a pharmaceutical composition for the prevention or treatment of diabetes comprising the above-mentioned zifenoid 75 or a pharmaceutically acceptable salt thereof .

In the method of the present invention for preventing or treating diabetes, the pharmaceutical composition is the same as that described above in connection with the pharmaceutical composition of the present invention.

The term "individual" as used herein refers to all animals, including mammals including humans, rats, livestock, and the like.

In the above-mentioned preventive or therapeutic method of the present invention, the dose, administration route and administration mode of the pharmaceutical composition are the same as those described above in connection with the pharmaceutical composition of the present invention.

In the above-mentioned preventive or therapeutic method of the present invention, the pharmaceutical composition may be administered orally or parenterally without particular limitation.

According to another aspect of the present invention, there is provided a food composition for preventing or improving diabetes comprising zifenoid 75 or a pharmaceutically acceptable salt thereof.

The ziphenoxide 75 of the present invention may preferably be a ziphenocide 75 having the structure of the following formula (1).

[Chemical Formula 1]

Figure 112015041364097-pat00002

The ziphenoside 75 or a pharmaceutically acceptable salt thereof contained in the food composition of the present invention may be contained in the form of an animal, plant extract, extract thereof, a fraction thereof, or a processed product thereof containing ziphenocide 75. The composition may also include a food-acceptable food-aid additive.

As used herein, the term "food-aid additive " refers to a component that can be added to foods in a supplementary manner, and is appropriately selected and used by those skilled in the art as added to produce health functional foods of each formulation. Examples of food-aid additives include flavors such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and fillers, pectic acid and its salts, alginic acid and its salts, organic acids, , a pH adjusting agent, a stabilizer, a preservative, a glycerin, an alcohol, and a carbonating agent used in a carbonated drink. However, the types of the food auxiliary additives of the present invention are not limited by these examples.

A health functional food may be included in the food composition of the present invention. The term "health functional food " as used in the present invention refers to a food prepared and processed in the form of tablets, capsules, powders, granules, liquids and rings using raw materials and components having useful functions in the human body. Here, 'functional' refers to the structure and function of the human body to obtain nutritional effects and obtain useful effects for health use such as physiological action. The health functional food of the present invention can be prepared by a method commonly used in the art and can be prepared by adding raw materials and ingredients that are conventionally added in the art. In addition, the formulations of the above health functional foods may also be manufactured without limitations as long as they are acceptable as health functional foods. The composition for food of the present invention can be manufactured in various forms, and unlike general pharmaceuticals, it has an advantage of being free from side effects that may occur when a food is used as a raw material for a long period of time, and is excellent in portability. Health functional foods can be taken as an adjunct to promote the prevention or improvement of diabetes.

The form of the health functional food of the present invention is not limited, and may include all foods in the conventional meaning, and may be used in combination with terms known in the art such as functional foods. In addition, the health functional food comprising the zifenoid 75 of the present invention can be prepared by mixing with other suitable auxiliary ingredients that can be contained in food according to the selection of a person skilled in the art, and known additives. Examples of foods that can be added include dairy products, such as meat, sausage, bread, chocolates, candies, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, Vitamin complex, and the like, and can be prepared by adding to the juice, tea, jelly, juice, and the like, which is produced by using the Zifenose 75 as a main component according to the present invention.

At this time, the content of the extract contained in the food composition is not particularly limited, but may be 0.01 to 100% by weight, more preferably 1 to 80% by weight based on the total weight of the food composition.

According to another aspect of the present invention, there is provided a feed composition for preventing or improving diabetes comprising zifenoid 75 or a pharmaceutically acceptable salt thereof.

The ziphenoxide 75 of the present invention may preferably be a ziphenocide 75 having the structure of the following formula (1).

[Chemical Formula 1]

Figure 112015041364097-pat00003

The feed compositions of the present invention may be feed compositions such as poultry such as cattle, pigs, birds, chickens, ducks, poultry, fishes, crustaceans, etc. However, the feed composition is not limited thereto and any animals that can ingest zifenoid 75 may use the present invention It is obvious that it can be carried out.

The feed composition of the present invention is usable regardless of the compounding ratio in the feed composition. For example, even a feed having a high protein content has no problem in using the present invention.

At this time, the content of the extract contained in the feed composition is not particularly limited, but may be 0.01 to 100% by weight, more preferably 1 to 80% by weight based on the total weight of the feed composition.

The feed composition of the present invention can be used for food processing, such as cereals such as corn, wheat bran, wheat bran, corn bran, soybean meal, pasta such as sweet potato and potato, baking by-product, amino acid fermentation by- Such as corn oil, soybean oil, corn oil, soybean oil, corn oil, soybean oil, corn oil, soybean oil, starch, etc., proteins such as fish meal, Inorganic salts such as bone fragments, fish bone fragments, and bone fragments, salt salts such as light salts and sun salt, phosphates, calcium salts and the like.

The feed composition of the present invention may contain at least one additive selected from the group consisting of guar gum, rosin, gella team, casein, binders such as sodium alginate and sodium caseinate, emulsifiers such as sucrose fatty acid esters and sorbitan fatty acid esters, Antioxidants such as ethoxylate, butylhydroxytoluene and the like, and the like.

The feed composition of the present invention may further comprise an enzyme preparation such as an amino acid preparation, a vitamin preparation, a sugar chain enzyme, a probiotics such as Lactobacillus lutei, a yeast such as a brewer's yeast, and the like.

The feed composition of the present invention is not limited in its formulation and any commonly used feed composition can be used in the present invention. For example, the feed composition of the present invention can be a liquid, powder, granule, granule, pellet, or granule.

The composition containing ziphenocide 75 according to the present invention promotes insulin secretion and increases the activity of mitochondria to prevent and treat diabetes.

Figure 1 shows the results of ELISA quantitative analysis of the amount of insulin secreted by the administration of ziphenocide 75.
FIG. 2 shows the results of a method for measuring the amount of Luciferase activity on the amount of intracellular ATP increased by administration of Ziphenocide 75.
FIG. 3 shows Tetramethylrhodamine methyl ester (TMRM) staining and fluorescence activated cell sorting (FACS) analysis on mitochondrial membrane potential increased by administration of Zifenoid 75. FIG.

Hereinafter, the constitution and effects of the present invention will be described in more detail through examples. These examples are only for illustrating the present invention, and the scope of the present invention is not limited by these examples.

Example  One: Zifenoid  75 in insulin secretion increase effect

In order to confirm the effect of increasing the insulin secretion of Zipenoid 75, the amount of insulin secreted after treatment with Ziphenocide 75 was measured.

Specifically, insulin-secreting INS-1 cells were cultured in a cell incubator (37 ° C, 5% CO 2 , RPMI medium, 10% FBS) to confirm the effect of increasing insulin secretion by zifenoid 75, Cells were treated with 10 μM each of zifenoid 75, ginsenoside F1, ginsenoside Rg3, ginsenoside Rb2 and ginsenoside Rb3, and the amount of insulin secreted after treatment for 2 hours was measured by ELISA .

As a result, as shown in FIG. 1, it was confirmed that when ziphenoside 75 was treated, the insulin secretion amount was increased by about 110% as compared with the control (DMSO). Thus, it can be seen that diabetes can be prevented or treated by increasing the amount of insulin secretion by treatment with Zifenoid 75. It was confirmed that ginsenoside F1, ginsenoside Rg3, ginsenoside Rb2, and ginsenoside Rb3 had an insulin secretion increasing effect of about 50%.

Example  2: Zifenoid  Activation of mitochondrial function of 75

If mitochondrial function is impaired, diabetes may be caused by interference with insulin signaling. Therefore, in order to confirm the activation effect of mitochondrial function of zifenoid 75, increased amount of ATP and mitochondrial membrane voltage were measured after treatment with ziphenoside 75.

Specifically, insulin-secreting INS-1 cells were cultured in a cell culture incubator (37 ° C., 5% CO 2 , RPMI medium, 10% FBS) to confirm mitochondrial function activation by zifenoid 75, , And ziphenoside 75 (10 μM) were treated for 2 hours, and the amount of ATP in the cells and the mitochondrial membrane voltage were measured. First, to measure the amount of ATP in cells, INS-1 cells treated with zifenoid 75 were pulverized by freezing-thawing and ultrasonication, and the cell lysate was mixed with luciferase and luciferin to induce fluorescence. Since the activity of luciferase and the resulting fluorescence are dependent on the amount of ATP, the amount of ATP was determined by measuring the degree of fluorescence with a fluorescence analyzer. Next, in order to measure mitochondrial membrane potential, INS-1 cells treated with zifenoid 75 were stained with TMRM and the degree of staining of each cell was measured using a FACS instrument. The higher the mitochondrial membrane voltage, the higher the degree of TMRM staining.

As a result, as shown in FIG. 2, it was confirmed that when Zipenoid 75 was treated, the intracellular ATP amount was increased by about 50% as compared with the control (DMSO). In addition, it was confirmed that the ginsenoside F1, ginsenoside Rg3, ginsenoside Rb2, and ginsenoside Rb3 had about 40% increase in the amount of ATP. As shown in FIG. 3, when ziphenoside 75 was treated, it was confirmed that the mitochondrial membrane potential was increased by about 40% as compared with the control (DMSO). Ginsenoside F1, ginsenoside Rg3, ginsenoside Rb2, and ginsenoside Rb3 showed about 20% increase in mitochondrial membrane potential.

These results imply that ATP synthesis and mitochondrial membrane potential were increased by the activation of mitochondrial function when Zipenoid 75 was treated with cells. As a result, it can be seen that the functional activity of mitochondria according to the treatment of Zifenoid 75 can prevent or treat diabetes.

Claims (9)

A pharmaceutical composition for preventing or treating diabetes comprising zifenoid 75 or a pharmaceutically acceptable salt thereof.
2. The pharmaceutical composition according to claim 1, wherein the ziphenocide 75 is represented by the formula (1).

[Chemical Formula 1]
Figure 112015041364097-pat00004

The pharmaceutical composition of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier.
The pharmaceutical composition according to claim 1, wherein the diabetes is non-insulin dependent diabetes mellitus.
A method for preventing or treating diabetes comprising administering the pharmaceutical composition of any one of claims 1 to 4 to a subject other than a human.
A food composition for preventing or improving diabetes comprising zifenoid 75 or a pharmaceutically acceptable salt thereof.
7. The food composition according to claim 6, wherein the ziphenocide 75 is represented by the formula (1).

[Chemical Formula 1]
Figure 112015041364097-pat00005

Diazepine 75 or a pharmaceutically acceptable salt thereof.
9. The feed composition according to claim 8, wherein the ziphenocide 75 is represented by the formula (1).

[Chemical Formula 1]
Figure 112015041364097-pat00006

KR1020150059646A 2015-04-28 2015-04-28 Anti-diabetic effects of Gypenoside 75 KR101660834B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020150059646A KR101660834B1 (en) 2015-04-28 2015-04-28 Anti-diabetic effects of Gypenoside 75

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020150059646A KR101660834B1 (en) 2015-04-28 2015-04-28 Anti-diabetic effects of Gypenoside 75

Publications (1)

Publication Number Publication Date
KR101660834B1 true KR101660834B1 (en) 2016-10-11

Family

ID=57162191

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020150059646A KR101660834B1 (en) 2015-04-28 2015-04-28 Anti-diabetic effects of Gypenoside 75

Country Status (1)

Country Link
KR (1) KR101660834B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017191856A1 (en) * 2016-05-04 2017-11-09 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 Antidiabetic effect of gypenoside 75
KR101928553B1 (en) * 2018-08-07 2018-12-12 주식회사 모든바이오 A Composition for Preventing or Treating Inflammasome Mediated Inflammatory Disease Containing Ginsenoside Compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080003931A (en) * 2005-04-27 2008-01-08 주식회사 티지 바이오텍 Treatment of insulin resistance syndrome
WO2013089402A1 (en) * 2011-12-14 2013-06-20 (주)셀트리온 Composition comprising gypenoside extract of gynostemma pentaphyllum (thunb.) makino for treating or preventing type ιι diabetes, obesity, or hyperlipidemia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080003931A (en) * 2005-04-27 2008-01-08 주식회사 티지 바이오텍 Treatment of insulin resistance syndrome
WO2013089402A1 (en) * 2011-12-14 2013-06-20 (주)셀트리온 Composition comprising gypenoside extract of gynostemma pentaphyllum (thunb.) makino for treating or preventing type ιι diabetes, obesity, or hyperlipidemia
KR20130069430A (en) * 2011-12-14 2013-06-26 (주)셀트리온 Composition for treating or preventing diabetes type ii, obesity, or hyperlipidemia comprising gypenoside extract of gynostemma pentaphyllum

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
World Journal of Gatroenterology, 21(7), 2058-2066, 2015 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017191856A1 (en) * 2016-05-04 2017-11-09 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 Antidiabetic effect of gypenoside 75
KR101928553B1 (en) * 2018-08-07 2018-12-12 주식회사 모든바이오 A Composition for Preventing or Treating Inflammasome Mediated Inflammatory Disease Containing Ginsenoside Compounds
WO2020032365A1 (en) * 2018-08-07 2020-02-13 주식회사 모든바이오 Composition, comprising ginsenoside compound, for preventing or treating inflammasome-mediated inflammatory disease

Similar Documents

Publication Publication Date Title
KR101912481B1 (en) Composition, glucose metabolism-improving agent, and method for improving glucose metabolism
JP2013053121A (en) Composition for improving in vivo metabolism parameter
CN107580496B (en) Anti-diabetic effect of gypenoside 75
KR101695848B1 (en) A composition comprising ginsenoside f2 for preventing or treating non-alcoholic liver disease
JP6157928B2 (en) Fat accumulation inhibitor in the liver
WO2011002033A1 (en) Glucose metabolism-improving agent and glucose metabolism-improving composition
JP6293099B2 (en) Use of ginsenoside F2 for prevention or treatment of liver diseases
KR101660834B1 (en) Anti-diabetic effects of Gypenoside 75
KR20160141027A (en) Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder
JP2013095723A (en) Preventing agent for arthritis
EP3103457A1 (en) Satiety maintaining agent and method for maintaining feeling of satisfaction
KR101732483B1 (en) Composition for prevention, improvement or treatment of peripheral neuropathy comprising Forsythiae Fructus extract as effective component
JP6976030B2 (en) Composition for prevention or improvement of non-alcoholic fatty liver disease
KR20200044766A (en) Composition for improving stress or depression comprising extract of Ishige sinicola
KR101629642B1 (en) Food composition, pharmaceutical composition, animal medicine and feed composition against fatty liver with piperlongumine
KR20190118961A (en) Composition for Preventing or Improving Muscle Atrophy Comprising Kukoamine A and Kukoamine B
KR101957502B1 (en) Composition for preventing or improving obsity, fatty liver and diabetes comprising Methyl Sulfonyl Methane: Dimethyl Sulfone
KR20190129244A (en) Composition for improving stress or depression comprising extract of Ishige sinicola
JP7329768B2 (en) Diabetes prophylactic and therapeutic agents, blood glucose level elevation inhibitors, blood glucose level spike inhibitors and glucose uptake inhibitors
CN111615392B (en) Autism spectrum disorder and mental disease improving agent
JP6842308B2 (en) Nocturnal postprandial blood glucose elevation inhibitor
EP2889038A1 (en) Composition for preventing or treating cancer containing extracts of artocarpus altilis fruits, leaves, or stems, or fractions thereof as active ingredients
KR101753244B1 (en) Composition comprising trigonelline as an active ingredient for care of hangover or protection of liver
JP2021161070A (en) Glp-1 secretion promoter
KR20220041265A (en) Composition for Preventing or Treating Muscular disease containing Valproic Acid

Legal Events

Date Code Title Description
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20190906

Year of fee payment: 4